Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 6, 2015, Pages 618-626

  Castañeda, Santos ^a   Martín Martínez, María A ^b   González Juanatey, Carlos ^c   Llorca, Javier ^d,e   García Yébenes, María J ^b   Pérez Vicente, Sabina ^b   Sánchez Costa, Jesús T ^b   Díaz Gonzalez, Federico ^b,f,g   González Gay, Miguel A ^h,i  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b UNIDAD DE INVESTIGACIÓN   (Spain)

^c Hospital Lucus Augusti   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^f UNIVERSIDAD DE LA LAGUNA   (Spain)

^g HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁱ Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases   (Spain)

Author keywords

Ankylosing spondylitis; Cardiovascular morbidity; Cardiovascular risk; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID;

ADULT; AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CORONARY RISK; CORRELATION ANALYSIS; DAS28; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; AGED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BODY MASS; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COHORT ANALYSIS; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; RHEUMATIC DISEASES; SMOKING; SPAIN; SPONDYLITIS, ANKYLOSING; TIME;

ADULT; AGED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PREVALENCE; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; RISK FACTORS; SMOKING; SPAIN; SPONDYLITIS, ANKYLOSING; TIME FACTORS;

EID: 84940208406     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.12.002     Document Type: Article

References (47)

1. Avina-Zubieta J.A., Thomas J., Sadatsafavi M., Lehman A.J., Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012, 71:1524-1529.
2. Dessein P.H., Joffe B.I., Veller M.G., Stevens B.A., Tobias M., Reddi K., et al. Traditional and non traditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005, 32:435-442.
3. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Lopez-Diaz M.J., Piñeiro A., Garcia-Porrua C., Miranda-Filloy J.A., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007, 57:125-132.
4. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005, 35:8-17.
5. Listing J., Kekow J., Manger B., Burmester G.R., Pattloch D., Zink A., et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 2013, [Epub ahead of print]. 10.1136/annrheumdis-2013-204021.
6. Aviña-Zubieta J.A., Choi H.K., Sadatsafavi M., Etminan M., Esdaile J.M., Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008, 59:1690-1697.
7. Goodson N., Marks J., Lunt M., Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005, 64:1595-1601.
8. Solomon D.H., Karlson E.W., Rimm E.B., Cannuscio C.C., Mandl L.A., Manson J.E., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303-1307.
9. Del Rincon I.D., Williams K., Stern M.P., Freeman G.L., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737-2745.
10. Peters M.J., van Halm V.P., Voskuyl A.E., Smulders Y.M., Boers M., Lems W.F., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009, 61:1571-1579.
11. Van Halm V.P., Peters M.J., Voskuyl A.E., Boers M., Lems W.F., Visser M., et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009, 68:1395-1400.
12. Meune C., Touze E., Trinquart L., Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009, 48:1309-1313.
13. Goodson N.J., Wiles N.J., Lunt M., Barrett E.M., Silman A.J., Symmons D.P. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002, 46:2010-2019.
14. Peters M.J., van der Horst-Bruinsma I.E., Dijkmans B.A., Nurmohamed M.T. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004, 34:585-592.
15. Heeneman S., Daemen M.J. Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 2007, 19:358-362.
16. Jamnitski A., Symmons D., Peters M.J., Sattar N., McInnes I., Nurmohamed M.T. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013, 72:211-216.
17. Horreau C., Pouplard C., Brenaut E., Barnetche T., Misery L., Cribier B., et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 2013, Suppl. 3:12-29.
18. Gladman D.D., Ang M., Su L., Tom B.D., Schentag C.T., Farewell V.T. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009, 68:1131-1135.
19. Gonzalez-Juanatey C., Llorca J., Miranda-Filloy J.A., Amigo-Diaz E., Testa A., Garcia-Porrua C., et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:287-293.
20. Gonzalez-Juanatey C., Llorca J., Amigo-Diaz E., Dierssen T., Martin J., Gonzalez-Gay M.A. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:1074-1080.
21. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993, 52:174-176.
22. Mathieu S., Gossec L., Dougados M., Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res 2011, 63:557-563.
23. Peters M.J., Symmons D.P., McCarey D., Dijkmans B.A., Nicola P., Kvien T.K., et al. EULAR evidence based recommendations for CV risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
24. Conroy R.M., Pyörälä K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
25. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818. (Addenda. Addendum I), [SCORE charts including HDL-C are available as Addendum I to these guidelines on the ESC website]. http://www.escardio.org/guidelines.
26. Corrales A., Parra J.A., González-Juanatey C., Rueda-Gotor J., Blanco R., Llorca J., et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2013, 72:1764-1770.
27. Corrales A., González-Juanatey C., Peiró M.E., Blanco R., Llorca J., González-Gay M.A. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 2014, 73:722-727.
28. Choi H.K., Hernán M.A., Seeger J.D., Robins J.M., Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177.
29. Dixon W.G., Watson K.D., Lunt M., Hyrich K.L., British Society for Rheumatology Biologics Register Control Centre Consortium, Silman A.J., et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007, 56:2905-2912.
30. Greenberg J.D., Kremer J.M., Curtis J.R., Hochberg M.C., Reed G., Tsao P., et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:576-582.
31. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
32. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
33. Moll J.M., Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973, 3:55-78.
34. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Piñeiro A., Garcia-Porrua C., Testa A., Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1219-1223.
35. Ward M.M. Interpreting studies of cardiovascular mortality in rheumatoid arthritis: the importance of timing. Arthritis Rheum 2008, 59:1687-1689.
36. Gonzalez-Gay M.A., Gonzalez-Juanatey C. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis 2014, 73:1281-1283.
37. Solomon A., Norton G.R., Woodiwiss A.J., Dessein P.H. Obesity and carotid atherosclerosis in African black and Caucasian women with established rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2012, 14:R67.
38. López-Mejías R., García-Bermúdez M., González-Juanatey C., Castañeda S., Miranda-Filloy J.A., Gómez-Vaquero C., et al. NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2012, 224:426-429.
39. López-Longo F.J., Oliver-Miñarro D., de la Torre I., González-Díaz de Rábago E., Sánchez-Ramón S., Rodríguez-Mahou M., et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009, 61:419-424.
40. Collantes E., Zarco P., Muñoz E., Juanola X., Mulero J., Fernández-Sueiro J.L., et al. Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. Rheumatology (Oxford) 2007, 46:1309-1315.
41. Michaud K., Vera-Llonch M., Oster G. Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis. J Rheumatol 2012, 39:54-59.
42. Cohen J.D., Dougados M., Goupille P., Cantagrel A., Meyer O., Sibilia J., et al. Health assessment questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis. J Rheumatol 2006, 33:1936-1941.
43. Michaud K., Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007, 21:885-906.
44. Radner H., Smolen J.S., Aletaha D. Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis 2010, 69:536-541.
45. Semb A.G., Rollefstad S., Provan S.A., Kvien T.K., Stranden E., Olsen I.C., et al. Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol 2013, 40:359-368.
46. Provan S.A., Semb A.G., Hisdal J., Stranden E., Agewall S., Dagfinrud H., et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 2011, 70:812-817.
47. Martín-Martínez M.A., González-Juanatey C., Castañeda S., Llorca J., Ferraz-Amaro I., Fernández-Gutiérrez B., et al. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis. Scientific evidence and expert opinion. Semin Arthritis Rheum 2014, (pii: S0049-0172(14)00003-1 [Epub ahead of print]). 10.1016/j.semarthrit.2014.01.002.